Skip to content
TrialMatch
Sign up
Recruiting Phase 1

A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerability of JMT108 at increasing doses and determine the dose and schedule to be used in the second part of the study (Phase 1a) * To assess effectiveness of JMT108 in participants with locally advanced or metastatic tumors (Phase 1b) * To evaluate how quickly JMT108 is metabolized by the body (pharmacokinetics or PK) * To evaluate if antibodies to the study drug develop (immunogenicity) * To evaluate preliminary efficacy to the drug * To explore the pharmacodynamic (PD) characteristics of JMT108 * To explore the correlation between biomarker levels and preliminary efficacy Participants will: * Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive JMT108 by intravenous injection every 2 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment * Be followed for progression every 3 months for up to 2 years

Condition
Cancer, Cancer (Solid Tumors)
Tested
JMT108
Sponsor
Conjupro Biotherapeutics, Inc.

Who can join

Age
18 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 17

  • Minimum age: 18 years
  • Study condition: Cancer, Cancer (Solid Tumors)
  • Major Inclusion Criteria:
  • Age ≥18 years
  • Participants with histologically or cytologically confirmed locally advanced or metastatic solid tumors who are unresponsive or intolerant to all standard of care or have no standard of care available
  • At least one evaluable tumor lesion according to RECIST v1.1.
  • ECOG performance status score ≤2.
  • Expected survival ≥ 3 months
  • Major Exclusion Criteria:
  • Active central nervous system metastases and/or leptomeningeal metastases
  • AEs from prior therapy which have not recovered to Grade ≤1 or baseline as per NCI CTCAE v5.0
  • Prior therapy
  • Any other unapproved investigational drugs or treatments within 4 weeks prior to the first dose of the investigational drug (C1D1).
  • Chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy, or other anti-tumor therapies within 4 weeks prior to the first dose of the investigational drug, except in the following situations:
  • Nitrosoureas or mitomycin C within 6 weeks prior to the first dose of the investigational drug;
  • Use of oral fluoropyrimidines and small-molecule targeted drugs within 2 weeks or 5 half-lives of the drug (whichever is longer) prior to the first dose of the investigational drug;
  • Use of herbal medicine/products with anti-tumor indications within 2 weeks prior to the first dose of the investigational drug.

Where

3 sites, 3 recruiting

NEXT Dallas

Dallas, Texas, United States

Recruiting

NEXT Virginia

Fairfax, Virginia, United States

Recruiting

Carolina BioOncology Institute

Huntersville, North Carolina, United States

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.